Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Myriad Genetics (MYGN)
NASDAQ:MYGN
Holding MYGN?
Track your performance easily
MYGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.87 - $29.30
Previous CloseN/A
Volume154.82K
Average Volume (3M)991.27K
Market Cap
$1.35B
Enterprise Value$2.53B
Total Cash (Recent Filing)$159.00M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.87
Next Earnings
Mar 04, 2025EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding91,035,230
10 Day Avg. Volume774,735
30 Day Avg. Volume991,269
Standard Deviation0.16
R-Squared0.38
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.64
Price to Cash Flow (P/CF)482.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.88
Enterprise Value/Revenue3.08
Enterprise Value/Gross Profit4.90
Enterprise Value/Ebitda-82.51
Forecast
1Y Price Target
$19.50Price Target Upside31.49% Upside
Rating ConsensusHold
Number of Analyst Covering8
Myriad Genetics News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceMYGN's new mid-term outlook calls for 12%+ revenue growth, indicating strong potential for future expansion.
Investment PotentialValuation is compelling with shares now at a significant discount to peers, suggesting attractive investment potential.
Portfolio DiversificationMyriad has expanded GeneSight coverage with 18 new contracts and 29 new coverage wins.
Bears Say
Competitive PressuresCompetitive pressures are rising for Prolaris, which is likely to face headwinds from updated prostate guidelines favoring competitors.
Market Outlook And ValuationThe growth outlook for Myriad Genetics has been downgraded due to worsening market conditions, resulting in a lowered price target.
Reimbursement ChallengesReimbursement pressure has been a consistent story for Myriad with UnitedHealthcare restricting access to GeneSight under its commercial plans being the latest example, which is expected to have revenue headwinds.
---
Ownership Overview
3.50% Insiders
25.69% Mutual Funds
0.06% Other Institutional Investors
41.46% Public Companies and Individual Investors
MYGN FAQ
What was Myriad Genetics’s price range in the past 12 months?
Myriad Genetics lowest stock price was $12.87 and its highest was $29.30 in the past 12 months.
What is Myriad Genetics’s market cap?
Myriad Genetics’s market cap is $1.35B.
When is Myriad Genetics’s upcoming earnings report date?
Myriad Genetics’s upcoming earnings report date is Mar 04, 2025 which is in 51 days.
How were Myriad Genetics’s earnings last quarter?
Myriad Genetics released its earnings results on Nov 07, 2024. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.019 by $0.041.
Is Myriad Genetics overvalued?
According to Wall Street analysts Myriad Genetics’s price is currently Undervalued.
Does Myriad Genetics pay dividends?
Myriad Genetics does not currently pay dividends.
What is Myriad Genetics’s EPS estimate?
Myriad Genetics’s EPS estimate is 0.03.
How many shares outstanding does Myriad Genetics have?
Myriad Genetics has 91,035,230 shares outstanding.
What happened to Myriad Genetics’s price movement after its last earnings report?
Myriad Genetics reported an EPS of $0.06 in its last earnings report, beating expectations of $0.019. Following the earnings report the stock price went down -1.471%.
Which hedge fund is a major shareholder of Myriad Genetics?
Currently, no hedge funds are holding shares in MYGN
---
Myriad Genetics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$19.50 (31.49% Upside)
$19.50 (31.49% Upside)
Blogger Sentiment
Bullish
MYGN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.69%
12-Months-Change
Fundamentals
Return on Equity
-16.39%
Trailing 12-Months
Asset Growth
-5.90%
Trailing 12-Months
Company Description
Myriad Genetics
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
---
MYGN Company Deck
---
MYGN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed sentiment with strong revenue growth and strategic investments highlighting the company's performance. However, significant challenges were noted, particularly the potential revenue impact from UnitedHealthcare's policy change and slower growth in certain segments.Read More>---
MYGN Stock 12 Month Forecast
Average Price Target
$19.50
▲(31.49% Upside)
Technical Analysis
Best Analysts Covering MYGN
1 Year
1 Year Success Rate
5/8 ratings generated profit
1 Year Average Return
+0.85%
reiterated a sell rating 2 months ago
Copying Rachel Vatnsdal's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +0.85% per trade.
---